SOP Lipidmanagement

Eine Fettstoffwechselstörung findet sich sehr häufig und ist einer der entscheidenden und gut behandelbaren kardiovaskulären Risikofaktoren. Insbesondere das LDL-Cholesterin ist an der Entstehung und Progression atherosklerotischer Gefäßerkrankungen, wie der koronaren Herzerkrankung, beteiligt. Durch eine frühzeitige und adäquate Therapie einer Fettstoffwechselstörung können Morbidität und Letalität kardiovaskulärer Erkrankungen reduziert werden.

• Literatur

• 1 Emerging Risk Factors Collaboration. Di Angelantonio E, Sarwar N. et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000 doi:10.1001/jama.2009.1619
• 2 Cholesterol Treatment Trialistsʼ (CTT) Collaboration. Fulcher J, OʼConnell R. et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385: 1397-1405 doi:10.1016/S0140-6736(14)61368-4
• 3 Catapano AL, Graham I, De Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37: 2999-3058 doi:10.1093/eurheartj/ehw272
• 4 Cholesterol Treatment Trialistsʼ Collaboration. Baigent C, Blackwell L. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681 doi:10.1016/S0140-6736(10)61350-5
• 5 Weng TC, Yang YH, Lin SJ. et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010; 35: 139-151 doi:10.1111/j.1365-2710.2009.01085.x
• 6 Cholesterol Treatment Trialistsʼ (CTT) Collaborators. Mihaylova B, Emberson J. et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590 doi:10.1016/S0140-6736(12)60367-5
• 7 Boekholdt SM, Hovingh GK, Mora S. et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014; 64: 485-494 doi:10.1016/j.jacc.2014.02.615
• 8 Cannon CP, Blazing MA, Giugliano RP. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-2397 doi:10.1056/NEJMoa1410489
• 9 Ridker PM, Revkin J, Amarenco P. et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 2017; 376: 1527-1539 doi:10.1056/NEJMoa1701488
• 10 Sabatine MS, Giugliano RP, Keech AC. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-1722 doi:10.1056/NEJMoa1615664
• 11 Landmesser U, Chapman MJ, Farnier M. et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J 2017; 38: 2245-2255 doi:10.1093/eurheartj/ehw480
• 12 Landmesser U, Chapman MJ, Stock JK. et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J 2017; DOI: 10.1093/eurheartj/ehx549.